Characterization of monoclonal antibodies raised to C-terminal peptides of ps2: A major trefoil peptide and motility factor expressed in adenocarcinomas and regions of mucosal injury

Human Pathology

Volumn 27, Issue 12, 1996, Pages 1259-1266

  Williams, R ^b   Elia, G ^b   Stamp, G W H ^b   Oates, T ^b   Wright, N A ^b   Lalani, E N ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

affinity chromatography; immunoprecipitation; monoclonal antibodies; pS2; trefoil peptides

Indexed keywords

2 DIETHYLAMINOETHANOL; CYANOGEN BROMIDE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BREAST ADENOCARCINOMA; CARBOXY TERMINAL SEQUENCE; CELL LYSATE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTESTINE ULCER; PEPTIDE ANALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PROGNOSIS;

EID: 0029852092     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90334-2     Document Type: Article

References (35)

1. Masiakowski P, Breathnach R, BlochJ, et al: Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast-cancer cell line. Nucl Acids Res 10:7895-7903, 1982
2. Nunez AM, Berry M, Imler J-L, et al: The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J 8:823-829, 1989
3. Mori K, Fujii R, Kida N, et al: Identification of a polypeptide secreted by human breast cancer cells (MCF-7) as the human estrogen-responsive gene (pS2) product. Biochem Biophys Res Commun 155:366-372, 1988
4. Rio M-C, Bellocq JP, Daniel JY, et al: Breast cancer-associated pS2 protein: Synthesis and secretion by normal stomach mucosa. Science 241:705-708, 1988
5. Prud'homme J-F, Jolivet A, Pichon M-F, et al: Monoclonal antibodies against native and denatured forms of estrogen-induced breast cancer protein (BCEI/pS2) obtained by expression in Escherichia coli. Cancer Res 50:2390-2396, 1990
6. May FEB, Westley BR: Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells. Cancer Res 46:6034-6040, 1986
7. May FEB, Westley BR: Identification and characterization of estrogen-regulated RNAs in human breast cancer cells. J Biol Chem 263:12901-12908, 1988
8. Skilton RA, Luqmani YA, McClelland RA, et al: Characterisation of a messenger RNA selectively expressed in human breast cancer. Br J Cancer 60:168-175, 1989
9. Wright NA, Poulsom R, Stamp GWH, et al: Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol 162:279-284, 1990
10. Henry JA, Nicholson S, Hennessy C, et al: Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: Relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br J Cancer 61:32-38, 1990
11. Henry JA, Bennett MK, Piggott NH, et al: Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 64:677-682, 1991
12. Luqmani YA, Ryall G, Shousha S, et al: An immunohistochemical survey of pS2 expression in human epithelial cancers. Int J Cancer 50:302-304, 1992
13. Welter C, Theisinger B, Seitz G, et al: Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. Lab Invest 66:187-192, 1992
14. Luqmani Y, Bennett C, Paterson I, et al: Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer 44:806-812, 1989
15. Theisinger B, Welter C, Seitz G, et al: Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma. Eur J Cancer 27:770-773, 1991
16. Seitz G, Theisinger B, Tomasetto G, et al: Breast cancer-associated protein pS2 expression in tumours of the biliary tract. Am J Gastroenterol 86:1491-1494, 1991
17. Foekens JA, van Putten PW, Portengen H, et al: Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol 37:815-821, 1990
18. Wysocki SJ, Hahnel E, Masters A, et al: Detection of pS2 messenger RNA in gynecological cancers. Cancer Res 50:1800-1802, 1990
19. Hoosein NM, Thim L, Jørgensen KH, et al: Growth stimulatory effect of pancreatic spasmolytic polypeptide on cultured colon and breast tumor cells. FEBS Lett 247:303-306, 1989
20. Dignass A, Lynch-Devaney K, Kindon H, et al: Trefoil peptides promote epithelial migration through a transforming growth factor b-independent pathway. J Clin Invest 94:376-383, 1994
21. Alison MR, Chinnery R, Poulsom R, et al: Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach. J Pathol 175:405-414, 1995
22. Williams R, Stamp GWH, Gilbert C, et al: pS2 Transfection of Murine Adenocarcinoma Cell Line (410.4) Enhances Dispersed Growth Pattern in 3-D Collagen Gel. J Cell Sci 109:63-71, 1996
23. Ey PL, Prowse SJ, Jenkin CR: Isolation of pure IgG1, IgG2a, and IgG2b immunoglobulins from mouse serum using protein A-Sepharose. Biochemistry 15:429-436, 1978
24. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981
25. Wright NA, Poulsom R, Stamp G, et al: Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 104:12-20, 1993
26. Hill CR, Thompson LG, Kenney AC: Immunopurification, in Harris ELV, Angal S (eds): Protein Purification Methods: A Practical Approach. Oxford, England, IRL Press, 1989, pp 282-292
27. Takahashi H, Kida N, Fujii R, et al: Expression of the pS2 gene in human gastric cancer cells derived from poorly differentiated adenocarcinoma. FEES Lett 261:283-286, 1990
28. Lalani EN, Jayaram Y, Williams R, et al: Effects of hSP on growth and proliferation of MCF 7 mammary carcinoma cells. J Pathol Suppl 175:109A, 1995
29. Thompson AM, Hawkins RA, Elton RA, et al: pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 68:93-96, 1993
30. Cappelletti V, Coradini D, Scanziani E, et al: Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur J Cancer 28A:1315-1318, 1992
31. Thor AD, Koerncr FC, Edgerton SM, et al: pS2 expression in primary breast carcinomas: Relationship to clinical and histological features and survival. Breast Cancer Res Treat 21:111-119, 1992
32. Henry JA, Piggott NH, Mallick UK, et al: pNR-2/pS2 immunohistochemical staining in breast cancer: Correlation with prognostic factors and endocrine response. Br J Cancer 63:615-622, 1991
33. Azzopardi JG, Muretto P, Goddeeris P, et al: "Carcinoid" tumours of the breast: The morphological spectrum of argyrophil carcinomas. Histopathology 6:549-569, 1982
34. Llorens MA, Bermejo MJ, Salcedo MC, et al: Epidermal growth factor receptors in human breast and endometrial carcinomas. J Steroid Biochem 34:505-509, 1989
35. Delarue JC, Friedman S, Mouriesse H, et al: Epidermal growth factor receptor in human breast cancers: Correlation with estrogen and progesterone receptors. Breast Cancer Res Treat 11:173-178, 1988